Probiotics and a toxin binder to slow chronic kidney disease
Part of Kidney & urinary clinical trials.
This trial studies an oral product (a “uremic toxin” absorber) plus probiotics to help slow the progression of chronic kidney disease. It may help by lowering harmful gut-related substances that can build up when kidney function is reduced.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 20 years or older at screening
- Have chronic kidney disease with eGFR between 15 and 45 and urine albumin-creatinine ratio (UACR) above 100
- Have had relatively stable kidney function, with creatinine not rising more than 0.3 mg/dL for at least 30 days
- Have enough nutrition and blood health (albumin at least 2.0 g/dL and hemoglobin at least 8 g/dL), and no active GI bleeding
- Not be on antibiotics or probiotics in the last 2 weeks (and be willing to avoid them during the study)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an oral absorbent plus probiotics can improve gut health and circulation in people who have chronic kidney disease and symptomatic peripheral artery disease (PAD). It will also track changes in blood markers and how well blood vessels function.
This study looks at a gene marker (“lncRNA,” a natural molecule in the body) to see how well an oral absorbent, with or without probiotics, is helping people with chronic kidney disease (CKD) who also have blocked leg arteries. It may help doctors better measure treatment impact and tailor care.
This trial tests if taking Xiqing (a Chinese herbal product) and probiotics together can help people with chronic kidney disease (CKD) by improving gut health and making their medication work better. It is for patients with moderate to advanced CKD who do not need dialysis yet.
This research study tests an experimental treatment for people with chronic kidney disease who are not yet on dialysis. The goal is to see if the treatment is safe and how it affects kidney function.
This trial tests whether a special blend of probiotics and prebiotics (called a synbiotic) can improve gut health and reduce harmful waste products in the blood for people on hemodialysis.
This trial tests if an oral medication that absorbs toxins plus probiotics can reduce inflammation and slow kidney damage in people with diabetes-related kidney disease (DKD). It may help those with mild to severe kidney function loss.
Hear when a new CKD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.